

# A Comparison of Predictability of Cardiovascular Events between Each Metabolic Component in Patients with Metabolic Syndrome Based on the Revised National Cholesterol Education Program Criteria

In-Cheol Hwang,<sup>1</sup> Kyoung-Kon Kim,<sup>1</sup> Sun-Ha Jee,<sup>2</sup> and Hee-Cheol Kang<sup>3</sup>

<sup>1</sup>Department of Family Medicine, Gachon University of Medicine and Science, Incheon; <sup>2</sup>Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul; <sup>3</sup>Department of Family Medicine, Yonsei University College of Medicine, Seoul, Korea.

Received: April 17, 2010

Revised: June 12, 2010

Accepted: July 9, 2010

Corresponding author: Dr. Hee-Cheol Kang,  
Department of Family Medicine,  
Yonsei University College of Medicine,  
250 Seongsan-ro, Seodaemun-gu,  
Seoul 120-752, Korea.

Tel: 82-2-2228-2332, Fax: 82-2-362-2473

E-mail: kanghc@yuhs.ac

The authors have no financial conflicts of interest.

**Purpose:** The prevalence of metabolic syndrome (MetS) generally varies depending on its diagnostic definition, and many different definitions inevitably lead to substantial confusion and lack of comparability between studies. Despite extensive research, there is still no gold standard for the definition of MetS, which continues to be a matter of debate. In this study, we investigate whether and to what extent its individual components are related to the risk of cardiovascular disease (CVD) in Korean population. **Materials and Methods:** We used data from the 2005 Korea National Health and Nutrition Examination Survey, which is a nationally representative survey of the noninstitutionalized civilian population. The study sample consisted of 1,406 Korean adults (587 men, 819 women) who were diagnosed with MetS based on the revised National Cholesterol Education Program (NCEP) criteria. Central obesity is defined as a waist circumference cutoff point reported in Asia-Pacific criteria for obesity based on waist circumference by the World Health Organization. CVD was defined as presence of stroke, myocardial infarction, or angina pectoris on a medical history questionnaire. **Results:** The CVD prevalence among the subjects was 6.8% for men and 8.6% for women. Besides age, the components of MetS showing a significant difference in the number of CVD events were high fasting glucose (FG) in men and high blood pressure (BP) and high FG in women. After adjusting for gender and age, high FG was shown to yield a significant difference (odds ratio: unadjusted 2.08, adjusted 1.81), alone among all MetS components. However, after adjusting for only age, no significant difference was found. **Conclusion:** Fasting glucose level is the highest predicting factor for CVD in Korean patients with MetS based on the revised NCEP definition.

**Key Words:** Metabolic components, cardiovascular disease, fasting glucose

## © Copyright:

Yonsei University College of Medicine 2011

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## INTRODUCTION

Metabolic syndrome (MetS) is characteristically defined as a clustering condition

of cardiovascular risk factors including hyperglycemia, dyslipidemia, hypertension, and central obesity.<sup>1</sup> It can not only progress to overt diabetes<sup>2-4</sup> but also has close relationship with development and prognosis of cardiovascular disease (CVD).<sup>5</sup> Although there have been questions as to whether MetS predicts CVD beyond its individual components,<sup>6</sup> it is still meaningful to look into its diagnosis, management, and prevention in medicine or public health.

Despite the fact that the pathophysiology of MetS is yet not clearly known, it has been suggested that an increasingly sedentary life style and western dietary habits play a role in developing obesity and dysfunctional energy storage, which can mediate insulin resistance as well as the interaction of genetic factors, thereby contributing to recent trends.<sup>7</sup> With the rising obese population and worldwide life expectancy, the frequency of development of MetS does not seem to diminish for the foreseeable future.<sup>8</sup>

The conception of MetS has evolved since it was first defined by Reaven in 1988 to improve the understanding of links between insulin resistance and vascular disease. Several definitions have been introduced including the World Health Organization criteria, which emphasizes hyperglycemia and insulin resistance; the National Cholesterol Education Program (NCEP) guideline, which deems all metabolic components as equally important; and the International Diabetes Federation (IDF) definition, which regards central obesity as a necessary factor (Table 1). These diverse definitions have led to substantial confusion and to an inability to compare study results. Although confusion might be caused

by lower cutoff points for specific metabolic components or different criteria applied based on ethnicity, more critical issues, such as designating which components are essential, have led to large differences in prevalence.<sup>9,10</sup> So far, the majority of research into diagnostic criteria for MetS has been done in studies that support specific criteria by comparing the prevalence<sup>11</sup> or prospective incidence<sup>12,13</sup> of CVD in people who satisfy each criterion. Rarely have there been studies that investigate the relationship between each component and the prevalence of CVD,<sup>14,15</sup> and all previous studies have examined only the general population. In addition to metabolic components, however, there are many other factors that increase the risk of CVD. Thus, in order to compare the predictability of metabolic components for CVD, it would be more appropriate to study patients who have been diagnosed with MetS.

The purpose of the study was to investigate the relationship between the prevalence of CVD and each metabolic component using nationwide data for Koreans who were diagnosed with MetS according to the NCEP guidelines, in which specific factors were not weighted.

## MATERIALS AND METHODS

### Study population and data collection

This study was based on data obtained from the Third Korean National Health and Nutrition Examination Survey (KNHANES) of noninstitutionalized Korean civilians, which

**Table 1. Metabolic Syndrome Definitions from WHO, NCEP, and IDF**

	WHO (1999)	NCEP (2001)	IDF (2005)
Required	Insulin resistance*		WC <sup>†</sup> ≥ 94 cm in men or ≥ 80 cm in women
No. of abnormalities	≥ 2 of:	≥ 3 of:	≥ 2 of:
Obesity	WHR > 0.9 in men or > 0.85 in women; BMI ≥ 30 kg/m <sup>2</sup>	WC ≥ 102 cm in men or ≥ 88 cm in women	
Triglycerides	≥ 150 mg/dL	≥ 150 mg/dL	≥ 150 mg/dL
HDL cholesterol	< 40 mg/dL in men or < 50 mg/dL in women	< 40 mg/dL in men or < 50 mg/dL in women	< 40 mg/dL in men or < 50 mg/dL in women
Hypertension	≥ 140/90 mmHg	≥ 130/85 mmHg	≥ 130/85 mmHg
Glucose		≥ 110 mg/dL <sup>‡</sup>	≥ 100 mg/dL
Microalbuminuria	Albumin/creatinine ratio > 30 mg/g; Albumin excretion rate > 20 mcg/min		

WHO, World Health Organization; NCEP, National Cholesterol Education Program; IDF, international diabetes federation, WC, waist circumference; WHR, waist to hip ratio; BMI, body mass index; HDL, high density lipoprotein.

\*Insulin resistance in top 25%; glucose ≥ 110 mg/dL; 2-hour glucose ≥ 140 mg/dL.

<sup>†</sup>Waist circumference for Europids (someone of European Extraction, even if living elsewhere).

<sup>‡</sup>The American Diabetes Association recently suggested lowering this threshold to 100.

was conducted by the Korean Ministry of Health and Welfare in 2005. Detailed descriptions of the survey method have been provided elsewhere.<sup>16</sup> Briefly, this survey was a nationwide representative study that used a stratified, multi-stage probability sampling design for the selection of household units. This survey was composed of four parts: health interview, health behavior, health examination, and nutrition. The surveys were performed during face-to-face interviews with the family members of randomly selected households. We performed a cross-sectional analysis of the data from the subjects who completed the health interview and health behavior survey. We excluded individuals with incomplete data for the standardized physical examination, laboratory tests, and anthropometric measures. This resulted in a final analytical sample of 1,406 subjects (587 men, 819 women) with MetS among the 5,030 participants aged 19 years or older. The presence of CVD was defined as a physician's diagnosis of any of the following on the Health Interview Survey: stroke, myocardial infarction, and angina. Smokers were defined as those who were currently smoking at the time of the survey, regardless of the number of cigarettes smoked. Participants who exercised twice a week, regardless of type or length of the exercise, were considered to partake in exercise.

### Definition of the MetS

We used the revised NCEP criteria,<sup>17</sup> which were proposed by the National Heart, Lung, and Blood Institute/American Heart Association, and require at least three of the following components: 1) abdominal obesity (waist circumference  $\geq$  90 cm for Asian men or  $\geq$  80 cm for Asian women),<sup>18</sup> 2) triglycerides  $\geq$  150 mg/dL or receiving drug treatment, 3) high density lipoprotein (HDL) cholesterol  $<$  40 mg/dL for men or  $<$  50 mg/dL for women or receiving drug treatment, 4) systolic/diastolic blood pressure  $\geq$  130/85 mmHg or receiving drug treatment and 5) fasting plasma glucose  $\geq$  100 mg/dL or receiving drug treatment. The revised NCEP criteria had recommended a lower waist circumference cutoff for Asian-Americans because Asians are predisposed to insulin resistance, MetS, and type 2 diabetes at lower waist circumferences than Caucasians.

### Statistical analysis

Statistical analysis was performed using STATA SE 9 (STATA Corporation, Texas, USA) and *p* values of  $<$  0.05 were considered to be statistically significant. Comparisons of the number of patients with each metabolic risk factor ac-

ording to the presence of CVD were done by  $\chi^2$  test, and odds ratios (OR) were calculated using multiple logistic regression analysis to evaluate the predictability of each metabolic component. All data are summarized as mean  $\pm$  standard deviation or number (%).

## RESULTS

There were 1,406 subjects (587 males and 819 females) diagnosed with MetS according to the revised NCEP definition out of a total of 5,030 (2,076 males and 2,954 females). The mean age of those diagnosed was  $51.8 \pm 13.2$  for men (28.3%) and  $58.1 \pm 13.2$  years for women (27.7%). Information regarding various metabolic risk factors is shown in Table 2. CVD events occurred in 6.9% of men and 8.6% of women. Among these events, stroke occurred with the highest frequency for both men and women.

Table 3 shows differences in the percentage of CVD events based on each metabolic risk factor. The CVD group was significantly older than the non-CVD group in both men and women. In addition, there was a significant difference in high fasting glucose (FG) in men and high blood pressure (BP) and high FG in women. The percentage of current smokers or who had high triglyceride was higher in the non-CVD group; however, this was statistically insignificant. This is not irrelevant, considering standards of Korean health insurance coverage for lipid-lowering drugs and reverse causality due to cross sectional design.

Logistic regression analysis of CVD events for each component of MetS prior to correction showed that high BP and high FG were statistically significant (OR: high BP 2.16, high FG 2.08). After adjustment for age and gender, only high FG showed significance (OR 1.81)(Fig. 1). Gender differences, presented in Table 4, show that prior to adjustment, fasting glucose in men (OR 2.67, 95% CI 1.24-5.75) and high BP (OR 2.09, 95% CI 1.10-3.96) and high FG (OR 1.84, 95% CI 1.10-3.10) in women were significant. However, after being adjusted, no significant difference was found in either men or women.

## DISCUSSION

We analyzed the relationship between the prevalence of CVD and each metabolic component in a target population, which was not representative of the general population, but

**Table 2.** General Characteristics of Study Subjects\* by Gender

	Men	Women
Number	587	819
Age, yrs	51.8 ± 13.2	58.1 ± 13.2
Current smoker, n (%)	248 (42.3)	51 (6.2)
Exerciser <sup>†</sup> , n (%)	266 (45.3)	313 (38.2)
Total cholesterol, mg/dL	189.6 ± 34.1	197.0 ± 36.5
LDL cholesterol, mg/dL	113.5 ± 31.7	123.8 ± 33.1
HDL cholesterol, mg/dL	37.3 ± 7.2	41.0 ± 7.7
Fasting glucose, mg/dL	107.6 ± 28.9	104.6 ± 27.3
Systolic blood pressure, mmHg	130.9 ± 15.8	130.6 ± 19.1
Diastolic blood pressure, mmHg	86.1 ± 9.9	81.0 ± 10.1
Triglycerides, mg/dL	194.5 ± 73.9	161.3 ± 69.8
Waist circumference, cm	91.3 ± 6.8	86.9 ± 7.5
CVD events <sup>‡</sup> , n (%)	40 (6.8)	70 (8.6)
Stroke	23 (3.9)	36 (4.4)
MI	8 (1.4)	10 (1.2)
Angina	11 (1.9)	29 (3.5)

LDL, low density lipoprotein; HDL, high density lipoprotein; CVD, cardiovascular disease; MI, myocardial infarction.

\*All subjects were diagnosed with metabolic syndrome by National Cholesterol Education Program criteria.

<sup>†</sup>Subjects who exercise more than twice a week.

<sup>‡</sup>Diagnosed by physician as any of the followings: stroke, MI, or angina.

**Table 3.** Comparison of Frequency of Metabolic Risk Factors According to the Presence of Cardiovascular Disease

	Men			Women		
	No CVD	CVD	<i>p</i> value*	No CVD	CVD	<i>p</i> value*
Number	547	40		749	70	
Age, mean (SD)	51.15 (13.2)	60.60 (9.49)	< 0.001	57.40 (13.29)	65.26 (9.65)	< 0.001
Current smoker, n (%)	237 (43.33)	11 (27.50)	0.050	44 (5.87)	7 (10.00)	0.172
Exercise, n (%)	243 (44.42)	23 (57.50)	0.109	284 (37.92)	29 (41.43)	0.563
Abdominal obesity, n (%)	346 (63.25)	26 (65.00)	0.825	658 (87.85)	61 (87.14)	0.863
Triglycerides, n (%)	417 (76.23)	25 (62.50)	0.052	414 (55.27)	36 (51.43)	0.536
Low-HDL cholesterol, n (%)	415 (75.87)	32 (80.00)	0.554	690 (92.12)	65 (92.86)	0.827
Blood pressure, n (%)	432 (78.98)	36 (90.00)	0.094	523 (69.83)	57 (81.43)	0.041
Fasting blood glucose, n (%)	305 (55.16)	30 (75.00)	0.018	356 (47.53)	42 (60.00)	0.046


HDL, high density lipoprotein; CVD, cardiovascular disease.

\*Independent two sample t-test or  $\chi^2$  test were used.

was made up of patients who had been diagnosed with MetS using the revised NCEP criteria. The purpose of selecting these subjects would be first to clarify the differences for each factor associated with MetS; and second, to minimize the influence of risk factors other than metabolic components that may increase the risk of CVD. In this study, when additional analysis was performed on the general population of 5,030 subjects, we found that the factors showing significant differences between the groups with and without CVD numbered three for the men (excluding lipid abnormalities) and five for women. Before adjusting for age and smoking, the OR of women with high BP was

5.19, and after adjustment it was 2.50 (not shown in table).

In the present study, we found that the only significant factor relevant to CVD prevalence was high FG. Anderson, et al.<sup>14</sup> showed that high FG (OR = 1.23, 95% CI 1.06-1.43) and Low HDL (OR = 1.57, 95% CI 1.31-1.89) were significantly different among the individual MetS factors at risk for coronary artery disease after adjusting for age. However, secondary analysis for the risk of death or myocardial infarction showed that only high FG was significant (adjusted hazard ratio 1.46, 95% CI 1.17-1.82). Sixty-five percent of subjects had undergone coronary angiography at the start of the study because they were at high risk for coro-



**Fig. 1.** Odds ratio of each metabolic component for occurrence of cardiovascular events in all subjects. WC, waist circumference; TG, triglycerides; HDL, high density lipoprotein; BP, blood pressure; FG, fasting glucose.

**Table 4.** Predictability of Each Metabolic Component for Cardiovascular Disease by Logistic Regression Analysis According to Gender

	Men (n = 587)				Women (n = 819)			
	Crude OR (95% CI)	p value	Age-adjusted* OR (95% CI)	p value	Crude OR (95% CI)	p value	Age-adjusted* OR (95% CI)	p value
Abdominal obesity	1.13 (0.55 - 2.29)	0.740	1.15 (0.56 - 2.39)	0.702	1.17 (0.55 - 2.50)	0.676	1.18 (0.55 - 2.57)	0.668
Triglycerides	0.70 (0.34 - 1.42)	0.322	0.86 (0.41 - 1.80)	0.692	1.05 (0.63 - 1.73)	0.863	1.08 (0.64 - 1.80)	0.781
Low-HDL cholesterol	1.91 (0.83 - 4.40)	0.129	1.95 (0.84 - 4.57)	0.122	1.49 (0.57 - 3.93)	0.417	1.46 (0.55 - 3.90)	0.446
Blood pressure	2.53 (0.86 - 7.45)	0.092	2.05 (0.68 - 6.19)	0.201	2.09 (1.10 - 3.96)	0.024	1.38 (0.71 - 2.69)	0.340
Fasting blood glucose	2.67 (1.24 - 5.75)	0.012	2.08 (0.95 - 4.59)	0.067	1.84 (1.10 - 3.10)	0.021	1.69 (0.99 - 2.86)	0.051

OR, odds ratio; CI, confidence interval; HDL, high density lipoprotein.

\*Age was stratified into intervals of 10 years.

nary artery disease. More than 70% were found to have stenosis. Although this cannot be directly compared with our study, the results also show that high FG had a strong correlation with prevalence of CVD, similar to previous reports.

There is still some major controversy regarding the diagnostic criteria for MetS. One of these is regarding which criterion is the most appropriate. So far, various diagnostic criteria for MetS have been published based on the requirements of specific components. The IDF presented new diagnostic criteria that considers racial differences and also considers central obesity as a necessary component based on its strong correlation with insulin resistance and central

obesity in recent publications of the pathological mechanisms of MetS.<sup>19</sup> However, recent studies are somewhat skeptical of considering central obesity as a necessary component,<sup>20,21</sup> and we found no difference in central obesity between individuals with and without CVD, in both men and women. The second major controversy is that there are many other factors that have a great impact on risk for CVD besides the five metabolic components of the criteria, including age.<sup>22,23</sup> These components should also be considered in the diagnosis of MetS. In our study, the prevalence of CVD increased 1.76 times for men and 1.66 times for women with every 10 year increase in age, and this result

was shown to be statistically significant (not shown in table).

In the current study, a cutoff point of 100 mg/dL for fasting blood glucose was used, which had been recommended at the 2003 American Diabetes Association Conference<sup>24</sup> based on studies showing a high risk of developing diabetes or CVD in subjects with impaired glucose intolerance (IGT) and impaired fasting glucose (IFG), so-called prediabetes. Based on this information, a fasting blood glucose cutoff point of 100 mg/dL was proposed for the diagnostic criteria of MetS at the 2005 IDF conference. Despite the definition of MetS, significant results were observed for prediction of CVD in both men and women when the conventional cutoff point of 110 mg/dL was lowered to 100 mg/dL. This suggests that particular caution is necessary to prevent CVD in patients with high FG who have been diagnosed with MetS, at least according to the revised NCEP definition. Among the various diagnostic criteria used to diagnose MetS, the identification of insulin resistance, including IGT and IFG, as a necessary component may more appropriately support prediction of CVD.

It is already widely accepted that ethnically specific values must be applied to waist circumference (WC) cutoff points for central obesity, one of the components of MetS.<sup>25</sup> Recently Lee, et al.<sup>26</sup> published their research findings on the appropriate cutoff values for Koreans based on the 1998 KNHANES data. According to their study, the WC at which the risk for developing other metabolic components increased significantly compared to the general population was 90 cm for men and 85 cm for women. Their study was in accordance with the basic concept of clustering the five CVD risk factors for MetS; however, when CVD is considered as the final outcome of MetS, future studies will be needed to define the cutoff value at which the risk of CVD increases significantly.

There are two limitations to our study. First, the clarity of the cause and effect relationship is affected by the cross-sectional research design. Since the subjects had already been diagnosed with CVD, stringent blood pressure, weight, and blood sugar control were highly likely. In addition, the fact that a greater number of men without CVD events were current smokers underscores these limitations. Second, the inclusion of the clinical diagnosis of angina pectoris with CVD is ambiguous, because unlike myocardial infarction or stroke, angina pectoris can be diagnosed by symptoms alone without specific blood test results or radiographic findings.

In summary, the predictability of each component for

CVD events in patients with MetS was considerably diverse, and high FG had the highest of all of them. In patients with MetS diagnosed according to the revised NCEP criteria, aggressive management should be undertaken to reduce all standard risk factors, but particular and increased attention should be paid to preventing and treating diabetes.

## REFERENCES

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539-53.
2. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. *Diabetes Care* 2000;23:1242-8.
3. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM; San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. *Diabetes Care* 2003;26:3153-9.
4. Wang JJ, Qiao Q, Miettinen ME, Lappalainen J, Hu G, Tuomilehto J. The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a chinese population with high postprandial glucose. *Diabetes Care* 2004;27:2429-37.
5. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. *Diabetes Care* 2005;28:1769-78.
6. Ding EL, Smit LA, Hu FB. The metabolic syndrome as a cluster of risk factors: is the whole greater than the sum of its parts?: comment on "The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis". *Arch Intern Med* 2010;170:484-5.
7. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. *Am Heart J* 2005;149:33-45.
8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002;287:356-9.
9. Koehler C, Ott P, Benke I, Hanefeld M; DIG Study Group. Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study. *Horm Metab Res* 2007;39:632-5.
10. Moebus S, Hanisch JU, Aidelburger P, Bramlage P, Wasem J, Jöckel KH. Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS). *Cardiovasc Diabetol* 2007;6:22.
11. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevos IA, Karagiannis A; GREECE-METS Collaborative Group. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. *Int J Cardiol* 2007;117:204-10.
12. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Gallo-way JM, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. *Diabetes Care* 2007;30:1851-6.

13. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation* 2004;110:1251-7.
14. Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, et al. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? *Cardiology* 2004;101:185-93.
15. Taylor H, Liu J, Wilson G, Golden SH, Crook E, Brunson CD, et al. Distinct component profiles and high risk among African Americans with metabolic syndrome: the Jackson Heart Study. *Diabetes Care* 2008;31:1248-53.
16. Eum KD, Lee MS, Paek D. Cadmium in blood and hypertension. *Sci Total Environ* 2008;407:147-53.
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. *Cardiol Rev* 2005;13:322-7.
18. WHO/IASO/IOTF. The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne: Health Communications Australia; 2000.
19. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. *Metabolism* 1996;45:699-706.
20. Lee J, Ma S, Heng D, Tan CE, Chew SK, Hughes K, et al. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. *Diabetes Care* 2007;30:343-7.
21. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, González-Villalpando C, González-Sánchez JL, Martínez-Calatrava MJ, et al. Is waist circumference an essential component of the metabolic syndrome? *Diabetes Care* 2007;30:2141-2.
22. Rosenbaum P, Gimeno SG, Sanudo A, Franco LJ, Ferreira SR; Japanese-Brazilian Diabetes Study Group. Analysis of criteria for metabolic syndrome in a population-based study of Japanese-Brazilians. *Diabetes Obes Metab* 2005;7:352-9.
23. Nilsson PM, Engström G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions. *Diabet Med* 2007;24:464-72.
24. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003;26 Suppl 1:S5-20.
25. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. *Lancet* 2005;366:1059-62.
26. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. *Diabetes Res Clin Pract* 2007;75:72-80.